Regeneron Pharmaceuticals REGN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.61B-7.2% | $3.88B+3.5% | $3.75B+2.1% | $3.68B+21.4% | $3.03B-20.1% | ||
| —— | —— | —— | —— | —— | ||
| $1.54B-5.1% | $1.63B+10.2% | $1.48B+3.7% | $1.42B+7.1% | $1.33B-6.0% | ||
| $647.7M-16.4% | $775M+17.8% | $657.8M+3.7% | $634.2M+0.2% | $633M-20.1% | ||
| $2.96B-1.4% | $3B+10.2% | $2.73B+5.1% | $2.6B+6.5% | $2.44B-12.9% | ||
| $642.9M-26.9% | $879.9M-14.3% | $1.03B-4.9% | $1.08B+82.4% | $591.7M-40.2% | ||
| 17.8%-4.8pp | 22.7%-4.7pp | 27.3%-2.0pp | 29.4%+9.8pp | 19.5%-6.6pp | ||
| $12.9M+5.7% | $12.2M-36.8% | $19.3M+436% | $3.6M-58.6% | $8.7M-17.1% | ||
| $188.3M+15.0% | $163.8M-77.8% | $736.5M+67.7% | $439.2M+40.2% | $313.3M— | ||
| $831.2M-20.4% | $1.04B-40.8% | $1.76B+16.1% | $1.52B+67.8% | $905M-5.5% | ||
| $104M-47.8% | $199.1M-34.4% | $303.3M+139% | $127.1M+32.0% | $96.3M+138% | ||
| $727.2M-13.9% | $844.6M-42.2% | $1.46B+4.9% | $1.39B+72.1% | $808.7M-11.9% | ||
| 20.2%-1.6pp | 21.7%-17.1pp | 38.9%+1.0pp | 37.9%+11.2pp | 26.7%+2.5pp | ||
| $6.75-14.2% | $7.87-42.2% | $13.62+6.3% | $12.81+76.2% | $7.27-10.4% | ||
| $766.1M-25.3% | $1.02B-11.9% | $1.16B-4.2% | $1.21B+69.0% | $718.6M-35.6% | ||
| 21.2%-5.1pp | 26.4%-4.6pp | 31%-2.1pp | 33%+9.3pp | 23.7%-5.7pp | ||
| $642.9M-26.9% | $879.9M-14.3% | $1.03B-4.9% | $1.08B+82.4% | $591.7M-40.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Regeneron Pharmaceuticals's revenue?
- Regeneron Pharmaceuticals (REGN) generated $14.9B in revenue over the trailing twelve months, up 5.9% year over year.
- Is Regeneron Pharmaceuticals profitable?
- Regeneron Pharmaceuticals reported $4.4B in net income over the trailing twelve months, a 29.6% net margin.
- What are Regeneron Pharmaceuticals's profit margins?
- Gross margin is 93.9% and operating margin is 24.3%, with a 29.6% net margin.
- What is Regeneron Pharmaceuticals's earnings per share?
- Regeneron Pharmaceuticals's diluted EPS over the trailing twelve months is $41.05.
- Where does Regeneron Pharmaceuticals's income statement data come from?
- Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
